Highquality iPSC derived lines from patient and control human donors

Commercially available and consented iPSC lines

We have a commercial library of 70 iPSCs from a range of patient and healthy donors. The cell lines include those from healthy donors and those with: 

  • Alzheimer’s Disease 
  • Parkinson’s Disease 
  • Amyotrophic Lateral Sclerosis (ALS) 
  • Frontotemporal Dementia 
  • Friedreich’s Ataxia 
  • Huntington’s Disease 

Our axoLinesTM iPSCs are used for axoServicesTM custom lab services, made-to-order axoCellsTM projects and specific licensing arrangements. 

The lines are derived from patient and healthy samples. To ensure high-quality cells that more closely mimic in vivo physiology, we extract fibroblasts or PBMCs from consenting donors and reprogram them into iPSCs, guided by our decades of scientific experience. 

How axoLinesTM can support your research:

  • 70 lines from a wide range of healthy (10) and patient (60) donors 
  • Diverse library including sibling and familial partners 
  • 50:50 split of male/female donors to address sex disparities in biopharma research 
  • Our reputation for quality has led to collaboration with leading research institutes and top ten biopharma  


Disease No. of Line Specific Conditions Additional Information/Mutations
ALS 3 2 x symptomatic (1 x TDP43, 1 x SOD1), 1 x C9ORF72+ but asymptomatic
Ataxia 16 Spinocerebellar Ataxia (10) 3 x SCA2, 5 x SCA3, 1 x SCA6, 1 x SCA7
Friedreich’s Ataxia (6) 4 x symptomatic (FXN), 1 x familial (FXN) 1 x healthy with normal FXN
Dementia 18 Alzheimer’s (7) 1 x APOE3/E3, 2 x APOE3/E4, 1 x APOE4/E4, 3 x PSEN1 (A246L, M146 and L286V)
Frontotemporal Dementia (9) 3 x MAPT, 2 x Progranulin, 1 x TARDBP, 2 x VCP, and 1 x “at risk” patient.
Behavioural Variant Frontotemporal Dementia (bvFTD) (3) 3 x MAPT
Huntington’s   5 HTT including one asymptomatic carrier
Parkinson’s  14 Including 5 x Ataxin-3, 2 x PINK1 & PARK2, 1 x PINK1 & PARKIN, 1 x PINK1, 3 x SNCA, 2 x LRRK2



  • 70 characterised lines from patient and control donors 
  • 50:50 split of male/female donors 
  • 10 healthy (control) donors  
  • Human iPSCS from eight main therapy areas 

We want to know how we can help and welcome your enquiries on the form below.